CD64 CAR T Cells therapy (University Of Colorado Denver)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameCD64 CAR T Cells therapy (University Of Colorado Denver)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionHigh affinity immunoglobulin gamma Fc receptor I modulatorsT lymphocyte replacements
TargetsHigh affinity immunoglobulin gamma Fc receptor I
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Colorado Denver
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Colorado Denver
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A